Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia

References

• Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6(6):CD013165. doi:10.1002/14651858.CD013165.pub2
   PubMed Web of Science ®Google Scholar
• Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Diseases. 2010;56:387–393. doi:10.1053/j.ajkd.2010.01.020
   PubMed Web of Science ®Google Scholar
• Kessler C, Ng J, Valdez K, et al. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011;6:136–140. doi:10.1002/jhm.834
   PubMed Web of Science ®Google Scholar
• Scherr L, Ogden DA, Mead AW, et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;264:115–119. doi:10.1056/NEJM196101192640303
   PubMed Web of Science ®Google Scholar
• Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report. N Engl J Med. 1961;264:111–115. doi:10.1056/NEJM196101192640302
   PubMed Web of Science ®Google Scholar
• Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis. 2012;60(3):409–416. doi:10.1053/j.ajkd.2012.04.023
   PubMed Web of Science ®Google Scholar
• Lokelma. Package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207078s000lbl.pdf. Accessed July 12, 2022.
   Google Scholar
• Veltassa. Package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205739s016lbl.pdf. Accessed July 12, 2022.
   Google Scholar
• Fordtran JS, Locklear TW. Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis. 1966;11:503–521. PMID: 5937767. doi:10.1007/BF02233563
   PubMedGoogle Scholar
• Sandle GI, Hunter M. Apical potassium (BK) channels and enhanced potassium secretion in human colon. QJM Mon J Assoc Physicians. 2010;103:85–89. PMID: 19892809. doi:10.1093/qjmed/hcp159
   PubMed Web of Science ®Google Scholar
• Li L, Harrison SD, Cope MJ, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther. 2016;21:456–465. PMID: 26856345. doi:10.1177/1074248416629549
   PubMed Web of Science ®Google Scholar
• Pitt B, Garza D. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia. Expert Opin Drug Saf. 2018;17:525–535. PMID: 29667438. doi:10.1080/14740338.2018.1462335
   PubMed Web of Science ®Google Scholar
• Rossignol P, David L, Chan C, Conrad A, Weir MR. Safety and tolerability of the potassium binder patiromer from a global pharmacovigilance database collected over 4 years compared with data from the clinical trial program. Drugs Real World Outcomes. 2021;8:315–323. PMID: 34018121. doi:10.1007/s40801-021-00254-7
   PubMedGoogle Scholar
• Bhattarai S, Pupillo S, Man Singh Dangol G, Sarac E. Patiromer acetate induced hypercalcemia: an unreported adverse effect. Case Rep Nephrol. 2019;2019:3507407. PMID: 30863649. doi:10.1155/2019/3507407
   PubMedGoogle Scholar
• Wiederkehr MR, Mehta AN, Emmett M. Case report: patiromer-induced hypercalcemia. Clin Nephrol Case Stud. 2019;7:51–53. PMID: 31410346. doi:10.5414/CNCS109782
   PubMedGoogle Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151–161. PMID: 26172895. doi:10.1001/jama.2015.7446
   PubMed Web of Science ®Google Scholar
• Bushinsky DA, Spiegel DM, Gross C, et al. Effect of patiromer on urinary ion excretion in healthy adults. Clin J Am Soc Nephrol CJASN. 2016;11:1769–1776. PMID: 27679518. doi:10.2215/CJN.01170216
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211–221. PMID: 25415805. doi:10.1056/NEJMoa1410853
   PubMed Web of Science ®Google Scholar
• Pergola PE, Spiegel DM, Warren S, Yuan J, Weir MR. Patiromer lowers serum potassium when taken without food: comparison to dosing with food from an open-label, randomized, parallel group hyperkalemia study. Am J Nephrol. 2017;46:323–332. PMID: 29017162. doi:10.1159/000481270
   PubMed Web of Science ®Google Scholar
• Ag M, Ma G, Lz G, Mr S. Patiromer: a clinical review. Curr Med Res Opin. 2016;32. PMID: 26456884. doi:10.1185/03007995.2015.1106935
   Web of Science ®Google Scholar
• Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88:1427–1433. PMID: 26376130. doi:10.1038/ki.2015.270
   PubMed Web of Science ®Google Scholar
• Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32:820–828. PMID: 21208974. doi:10.1093/eurheartj/ehq502
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2019;394:1540–1550. PMID: 31533906. doi:10.1016/S0140-6736(19)32135-X
   PubMed Web of Science ®Google Scholar
• Rafique Z, Liu M, Staggers KA, et al. Patiromer for treatment of hyperkalemia in the emergency department: a pilot study. Acad Emerg Med. 2020;27:54–60. doi:10.1111/acem.13868
   PubMed Web of Science ®Google Scholar
• Rattanavich R, Malone AF, Alhamad T. Safety and efficacy of patiromer use with tacrolimus in kidney transplant recipients. Transplant Int. 2019;32:110–111. doi:10.1111/tri.13369
   PubMed Web of Science ®Google Scholar
• Lim MA, Sawinski D, Trofe-Clark J. Safety, effectiveness, and tolerability of patiromer in kidney transplant recipients. Transplantation. 2019;103:e281–e282. doi:10.1097/TP.0000000000002829
   PubMed Web of Science ®Google Scholar
• Schnelle K, Winters H, Pesavento T, Singh P. Largest experience of safety and efficacy of patiromer in solid organ transplant. Transplant Direct. 2020;6(9):e595. doi:10.1097/TXD.0000000000001037
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Gosmanova EO, Woods SD, et al. Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med. 2020;132(2):176–183. doi:10.1080/00325481.2019.1706920
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Rowan CG, Conrod A, et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int Rep. 2019;4:301–309. doi:10.1016/j.ekir.2018.10.020
   PubMed Web of Science ®Google Scholar
• Amdur RL, Paul R, Barrows ED, et al. The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis. Kidney Int. 2020;98(5):1331–1340. doi:10.1016/j.kint.2020.06.042
   PubMed Web of Science ®Google Scholar
• Murea M, Patel A, Highland BR, et al. Twice-weekly hemodialysis with adjuvant pharmacotherapy and transition to thrice-weekly hemodialysis: a pilot study. Am J Kidney Dis. 2021. doi:10.1053/j.ajkd.2021.12.001
   PubMed Web of Science ®Google Scholar
• Desai NR, Rowan CG, Alvarez PJ, et al. Hyperkalemia treatment modalities: a descriptive observational study focused on medication and healthcare resource utilization. PLoS One. 2020;15:e0226844. doi:10.1371/journal.pone.0226844
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. doi:10.1056/NEJMoa011303
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi:10.1056/NEJMoa011161
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–1435. doi:10.1056/NEJM198706043162301
   PubMed Web of Science ®Google Scholar
• Epstein M, Alvarez PJ, Reaven NL, et al. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2016;22(11 Suppl):s311–s324.
   PubMed Web of Science ®Google Scholar
• Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20:1217–1226. doi:10.1002/ejhf.1199
   PubMed Web of Science ®Google Scholar
• Trevisan M, Fu EL, Xu Y, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23:1698–1707. doi:10.1002/ejhf.2287
   PubMed Web of Science ®Google Scholar
• Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2020;97:42–61. doi:10.1016/j.kint.2019.09.018
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4–131. doi:10.1002/ejhf.2333
   PubMed Web of Science ®Google Scholar
• Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022. doi:10.1053/j.ajkd.2022.01.002
   PubMed Web of Science ®Google Scholar
• Butler J, Anker SD, Siddiqi TJ, et al. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. Eur J Heart Fail. 2021. doi:10.1002/ejhf.2386
   Web of Science ®Google Scholar
• Evangelidis N, Sautenet B, Madero M, et al. Investigators standardised outcomes in nephrology - chronic kidney disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials. 2021;22(1):612. doi:10.1186/s13063-021-05574-1
   PubMed Web of Science ®Google Scholar
• Das S, Dey JK, Sen S, Mukherjee R. Efficacy and safety of patiromer in hyperkalemia: a systematic review and meta-analysis. J Pharm Pract. 2018;31(1):6–17. doi:10.1177/0897190017692921
   PubMed Web of Science ®Google Scholar